The April 2026 rescheduling

The Department of Justice moved two narrow kinds of cannabis from Schedule I to Schedule III. The first is cannabis in an FDA-approved drug product. The second — the one that matters for an OMMA license holder — is cannabis sold under a state medical marijuana license.

Everything else stayed in Schedule I. Recreational. Unlicensed. Synthetic THC. Cannabis sold as food or supplements.

Three things came out of the order. A new federal registration pathway opened for state-licensed medical operators, with a 60-day window to file the easy way. The federal tax penalty under Section 280E stopped applying to state-licensed medical activity starting tax year 2026. And state-licensed medical activity now operates, federally, as a Schedule III substance instead of a Schedule I one.

Acting Attorney General Todd Blanche signed the order. The natural question is whether the word acting makes the order weaker. The answer is no.

An Acting AG holds the same legal authority as a confirmed one. The rescheduling power Congress gave to the office in 1970 sits with whoever holds the office at the moment of signing. Blanche held it. He used it.

The lawsuits being prepared against the order will probably mention the acting title in passing. None of them rest on it. The real legal fight is about the route the order used to make the change — not about who held the pen.

Four dates are floating around. Here they are, in order, with what each one actually means.

April 22, 2026 — the order was signed. Internal date. Doesn't do anything to anybody.

April 23, 2026 — the announcement. The day the news broke. The day the industry started moving. Doesn't carry legal weight on its own.

April 28, 2026 — published in the Federal Register. This is the day the order became law. If a date matters for federal-law purposes, it's this one.

January 1, 2026 — not a date the order took effect at all. It's the start of tax year 2026, which is the full year the Section 280E tax relief covers. People confuse the two and it's an easy mix-up to make.

Two dates carry weight going forward. April 28, when the order went live. And June 27, when the 60-day window to file for federal registration the easy way closes.

Final. Already law. Not a draft, not a proposal, not waiting on a comment period.

Most federal rules go through a process where the agency proposes a rule, takes public comment for months, considers what came in, and then issues a final version. That process didn't happen here. The order skipped it, using a different legal authority that lets the Attorney General issue a binding order directly.

That shortcut is part of why some groups are getting ready to challenge the order in court. The challenge isn't to whether the order is in force — it is — but to whether the shortcut was the right one to use. While that fight plays out, the order is the law.

Executive Order 14370 was the president's instruction to the agencies. Trump signed it on December 18, 2025. It told DOJ, HHS, Treasury, and FDA to move quickly on rescheduling cannabis in a way that lined up with U.S. treaty commitments.

The executive order itself didn't reschedule anything. Presidents don't reschedule drugs. Agencies do. The EO was the directive — get this done — and the April 23 order is the agencies delivering on it.

No. Congress didn't vote on this. The President didn't sign a bill. No new law was passed.

This surprises people, because changing the legal status of cannabis sounds like exactly the kind of thing Congress would have to do. It isn't. Congress already did that part — back in 1970, when it passed the Controlled Substances Act and gave the Attorney General the authority to move substances between schedules administratively. Every rescheduling that has ever happened has happened that way. Congress wrote the rules of the game; the agencies play it.

What is unusual here isn't the absence of Congress. It's which path inside the agency authority got used. The standard path involves a long scientific review and a public comment period. The path used here was a faster one tied to a treaty obligation. That choice is the part being challenged in court — not the underlying authority.

The official version is in the Federal Register, dated April 28, 2026. That's the version that controls if anything ever comes down to exactly what does it say.

The DEA Diversion Control Division also hosts a copy on its website, alongside the new regulations the order put in place. Treasury and the IRS have published their own separate notices on the tax side.

Three names. One event.

The Final Order is the legal action — the Attorney General signing the paper that moves cannabis between schedules. That's the move itself.

The Final Rule is the package of new regulations that come along with the move. A new registration pathway. New paperwork requirements. Updates to existing rules so they fit the new schedule. The order makes the change; the rule makes the change work.

The Federal Register publication is the official document that contains both, plus the agency's written explanation of why it did what it did. It's the version everyone cites.

In conversation, people use these terms interchangeably and it's usually fine. If you ever need to point to the official one, it's the Federal Register publication.

Most federal rules take a long time to change. The agency has to study the substance, ask experts, take public comment, weigh it all, and write a careful new rule. That whole process for cannabis got started back in 2024 — and it stalled out. The judge running it stepped aside, the proceeding sat dormant, and by early 2026 nobody was moving it forward.

So the government used a different path. A long time ago, the United States signed a worldwide agreement with most other countries about how drugs get categorized. There's a provision in U.S. law that says: if a drug needs to move so U.S. law matches what that agreement allows, the Attorney General can issue a direct order. No long study. No comment period.

That's the path they used. The reasoning: medical cannabis fits where the agreement allows medical drugs to sit. Schedule III is that spot. Move it there.

It's legal authority, real and on the books. But it's a path that was mainly built for adding restrictions to match the treaty, not for removing them. The argument that the path wasn't built for changes this large is what's going to court.

Two narrow things.

First, cannabis inside an FDA-approved prescription drug. The category is small today — Epidiolex is the main product in it — but it's the legal pathway for any future cannabis-derived drug that gets through FDA approval.

Second, and this is the one that matters for an OMMA license holder: cannabis sold under a state medical marijuana license. That covers the plant material, the extracts, the edibles, the topicals — anything moving through a state-licensed medical supply chain to a qualifying patient.

On the federal paperwork, drug codes 7362 (marijuana), 7353 (marijuana extract), and 7386 (naturally-derived Δ9-THC) apply depending on what you handle. Those are the numbers that go on DEA registration filings.

Everything the order didn't name. The two categories that moved are narrow — everything outside them stays where it was.

That includes recreational/adult-use cannabis. It includes unlicensed cannabis, even where state law allows certain unlicensed activity. It includes synthetic THC products. It includes cannabis sold as food, as a dietary supplement, or as an unapproved drug (the FDA piece — separate from how the DEA schedules it). And it includes extracts that don't fall under either the FDA-approved-drug category or a state medical license.

The leftovers are bigger than the categories that moved. That's the part the news coverage tends to miss.

Three ways to read the line.

By activity: cultivation, processing, distribution, and dispensing performed under an OMMA license.

By product: flower, extracts, edibles, topicals — anything produced and moved inside the licensed medical supply chain.

By transaction: transfers between OMMA-licensed entities, and sales to qualifying medical patients.

The important thing to understand: the schedule status follows the license, not the plant. The same chemical compound is Schedule III when it's moving through a state-licensed medical channel, and Schedule I when it's moving through an unlicensed or recreational channel. The molecule doesn't change. The legal status does.

It's the category for cannabis-derived prescription medicines that have gone through the FDA approval process.

Today there's essentially one product in it: Epidiolex, a cannabidiol oral solution prescribed for certain rare pediatric epilepsy syndromes. A handful of other cannabis-derived drugs are working their way through FDA — some closer than others. Anything that gets approved drops into this category automatically.

It's a small category right now. Long-term, it's the legal lane for any pharmaceutical-grade cannabis product.

No. Recreational cannabis is still in Schedule I. The order didn't address it.

There is a separate proceeding underway that might eventually move recreational too — the DEA hearing scheduled for June 29, 2026 is the start of it. But that's a slower process, and any rule that comes out of it won't take effect in 2026. Late 2027 is the optimistic timeline. 2028 is more realistic.

For now, recreational is where it was.

Still Schedule I from the DEA's side. And separately, still a problem from the FDA's side.

The FDA treats cannabis-containing products that haven't gone through drug approval as either unapproved drugs (if anyone is making health claims about them) or as products that don't fit the food and supplement categories. The rescheduling order didn't change any of that.

For an operator producing cannabis-infused food or beverages under an OMMA license, the situation is layered. The product is Schedule III for federal controlled-substance purposes — because it's state-licensed medical. But it can still face FDA enforcement on a completely separate track if it's marketed in a way that triggers the FDA's drug or supplement rules. Two regulators, two frameworks, one product.

The order doesn't say. The federal text talks about "marijuana subject to a state medical marijuana license," and OMMA patient cards are state-issued authorization under the medical marijuana program — but a patient card isn't structured the same as a commercial license.

The honest answer is that home grow under a patient card is in a gray area. DEA hasn't issued specific guidance on it. The conservative read is that the order was written with commercial licensees in mind and patient home grow wasn't the target either way.

For a commercial operator, this question usually comes up because patients ask. The best framing for the patient: nothing about your right to grow at home under your OMMA card changed because of the federal order. State law governs that, and state law didn't move.

Same question, same gray area as patient home grow. OMMA's caregiver designation runs through the patient-card system rather than through a separate caregiver license — which is what makes the federal question fuzzy.

If the federal text "marijuana subject to a state medical marijuana license" is read narrowly as commercial licensing only, caregiver cultivation sits outside it. If read broadly as any state authorization, it sits inside. DEA hasn't picked.

Like the home-grow question: caregivers operating under OMMA designations didn't lose any state-law authority. The federal change is silent on them.